MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Which stem cell donor is best for kids with leukemia? major trial aims to find out
Disease control OngoingThis phase 3 trial compares two types of stem cell transplants for children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). One uses a half-matched family donor (haploidentical), the other a fully matched unrelated donor. The goal is to see w…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for kids with blood cancer: tailored treatments aim to boost cure rates and cut side effects
Disease control OngoingThis study tests whether using each child's unique genetic information to guide treatment can improve outcomes for acute lymphoblastic leukemia and lymphoma. About 790 children aged 1-18 will receive a combination of chemotherapy and newer targeted therapies, such as CAR T cells …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2, PHASE3 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to stop leukemia relapse after transplant
Disease control OngoingThis phase 2 trial tests whether combining venetoclax and azacitidine after a stem cell transplant can prevent leukemia from returning in high-risk patients. About 100 adults aged 18-75 with certain types of acute leukemia who are in remission after transplant will receive the dr…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Promising leukemia combo trial pulled before it began
Disease control TerminatedThis study aimed to find a safe dose of revumenib when given with standard chemotherapy drugs for children and young adults with acute leukemia. It was designed for patients with certain genetic markers. However, the trial was withdrawn before any participants were enrolled, so n…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough leukemia: experimental drug targets genetic flaw
Disease control OngoingThis study tests a new drug called ziftomenib (KO-539) in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a specific genetic change (MLL rearrangement or NPM1 mutation) found in some patients. The goal is to find the saf…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Leukemia drug trial pulled before it even started
Disease control TerminatedThis was a very early (Phase 1) study to test the safety of a new drug called MT-0169 in people with certain types of acute leukemia (AML or T-ALL) that had come back or not responded to treatment. The drug was given through a vein. However, the study was withdrawn before any pat…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New targeted therapy combo takes on tough leukemia
Disease control OngoingThis early-phase trial tests a new targeted drug called pivekimab sunirine (PVEK) alongside a standard chemotherapy regimen (FLAG-Ida) in 30 adults with newly diagnosed, high-risk acute myeloid leukemia or related blood cancers. PVEK works like a smart bomb, attaching to a protei…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising leukemia drug tested as maintenance after transplant in kids
Disease control TerminatedThis study was designed to test the safety and best dose of the drug revumenib in children and young adults with certain types of leukemia (ALL, AML, or mixed phenotype) after they have received a stem cell transplant. The goal was to see if revumenib could help prevent the cance…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo aims to tame tough leukemia in kids
Disease control OngoingThis phase 3 trial tests imatinib, a targeted cancer drug, with two different chemotherapy backbones in children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if a less intense chemo regimen works as well as the s…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New cocktail of cancer drugs shows promise in early leukemia trial
Disease control OngoingThis early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when com…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New engineered graft aims to improve stem cell transplants for kids with leukemia
Disease control TerminatedThis study tests a specially engineered donor graft called Orca-Q in children and young adults with blood cancers who need a stem cell transplant. The graft is designed to help the new cells take hold and reduce complications. The trial is currently on hold, but aims to enroll 40…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Younger donors may improve stem cell transplant success for leukemia patients
Disease control OngoingThis study compares stem cell transplants from two types of donors for people with leukemia or myelodysplastic syndromes (MDS): younger non-family members (age 40 or under) and older first-degree relatives (over 50). The goal is to see which donor leads to better overall survival…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for blood cancer patients: using mismatched donors for transplants
Disease control OngoingThis study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New stem cell mix aims to make transplants safer for blood cancer patients
Disease control OngoingThis phase 3 trial tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. Orca-T is a special mix of stem cells and immune cells from a matched donor, designed to reduce a serious side effect called graft-versus-host disease. The study compares …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New pill shows promise for tough leukemias in early trial
Disease control OngoingThis study tests an oral drug called BN104 in adults and adolescents with acute leukemia that has come back or not responded to treatment. The drug targets specific genetic changes (KMT2A rearrangement or NPM1 mutation) that drive the cancer. The trial aims to check safety, how t…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Second-Chance stem cell therapy for blood cancer patients
Disease control TEMPORARILY_NOT_AVAILABLEThis program gives patients with certain blood cancers access to Orca-T, a donor stem cell therapy, when the commercial version cannot be used. It is for people who have no other treatment options. The program monitors safety but does not test if the therapy works.
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug cocktail shows promise for tough childhood leukemia
Disease control OngoingThis trial is testing whether adding two targeted drugs, venetoclax and navitoclax, to standard chemotherapy can help children and young adults with acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. The study has two phases: first, finding the b…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Liver shield: nutrient may prevent chemo side effect in young leukemia patients
Symptom relief OngoingThis study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. About 440 participants will receive either chemotherapy alone or chemotherapy plus levocar…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC